Patient P-02299
Therapy response
Stable
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
66%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 13 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 68 SC-12 recommended — Supportive Compound SC-12
- Day 69 Patient accepted — Started SC-12 in the companion
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 75 No meaningful change — Supportive Compound SC-12
- Day 80 GI symptom burden −36% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
- Day 92 ME-01 recommended — Monitoring Escalation ME-01
- Day 93 Patient accepted — Started ME-01 in the companion
- Day 96 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 13.
Primary contributors, last 14 days
- Treatment adherence-18
- GI instability+8
- Inflammatory activity+6
- Toxicity-4
- Nutritional resilience+2
What helped?
- Supportive Compound SC-12Day 68Result: no meaningful change
- GI Support Protocol GI-04Day 71Result: symptom burden −36%
- Monitoring Escalation ME-01Day 92Result: deterioration detected before clinical escalation
LIFE OS recommendation
Clinician Review CR-01
76%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑65
- WearableResting HR 75 bpm
- Wearable1,866 steps/day
- WearableShort sleep window
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
- Mucosal barrier integrity ↓30
- Daily logGI symptom score 49 and rising
- WearableSleep 5.5 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 2.8 · butyrate capacity 25/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 6.0 h
- Steps
- 2,777
- Resting HR
- 72 bpm
Daily log: GI score 49, nutritional resilience 45, adherence 63.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02410 | 33% | S01 | GI-04 | improved | 55 |
| P-02054 | 31% | S01 | CR-01 | improved | 57 |
| P-02018 | 29% | S01 | GI-04 | improved | 46 |
| P-02409 | 28% | S01 | SC-12 | no change | 54 |
| P-02276 | 27% | S01 | — | — | 57 |
| P-02307 | 27% | S01 | — | — | 55 |
| P-02437 | 27% | S01 | — | — | 64 |
| P-02550 | 27% | S01 | — | — | 70 |
| P-02598 | 27% | S01 | — | — | 53 |
| P-02217 | 26% | S01 | — | — | 61 |
| P-02424 | 26% | S01 | — | — | 62 |
| P-02138 | 25% | S01 | — | — | 79 |